{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:58:21Z","timestamp":1778561901083,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":1181,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"the Diabetes Association of the R.O.C."},{"name":"the Collaboration Center of Health Information Application (CCHIA)"},{"name":"the Department of Health, Executive Yuan, Taiwan"},{"name":"the National Health Research Institute, Taiwan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jfma.2012.09.009","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T21:31:08Z","timestamp":1351200668000},"page":"617-624","source":"Crossref","is-referenced-by-count":31,"title":["National trends in anti-diabetic treatment in Taiwan, 2000\u20132009"],"prefix":"10.1016","volume":"111","author":[{"given":"Chia-Hsuin","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Der","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Low-Tone","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Ming","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2012.09.009_bib1","series-title":"Diabetes atlas","author":"International Diabetes Federation","year":"2011"},{"key":"10.1016\/j.jfma.2012.09.009_bib2","series-title":"Diabetes fact sheet (312)","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.jfma.2012.09.009_bib3","unstructured":"Centers for Disease Control Diabetes Statistics 2010. Available\u00a0at: http:\/\/www.cdc.gov\/nchs\/fastats\/diabetes.htm. [accessed in June, 2012]."},{"key":"10.1016\/j.jfma.2012.09.009_bib4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.24.11.1936","article-title":"Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S","volume":"24","author":"Boyle","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2012.09.009_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/jama.2009.726","article-title":"Diabetes in Asia. Epidemiology, risk factors, and pathophysiology","volume":"301","author":"Chan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2012.09.009_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1464-5491.2010.03007.x","article-title":"Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999\u20132004: a national health insurance data set study","volume":"27","author":"Chang","year":"2010","journal-title":"Diab Med"},{"key":"10.1016\/j.jfma.2012.09.009_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/diacare.26.3.917","article-title":"Economic costs of diabetes in the US in 2002","volume":"26","author":"Hogan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2012.09.009_bib8","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archinte.164.10.1134","article-title":"Trends in the complexity of diabetes care in the United States from 1991\u20132000","volume":"164","author":"Grant","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2012.09.009_bib9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medication for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2012.09.009_bib10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1185\/030079906X112598","article-title":"Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study","volume":"22","author":"Hanefeld","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jfma.2012.09.009_bib11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2012.09.009_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1479164112441524","article-title":"Alpha-glucosidase inhibitors 2012 \u2013 cardiovascular considerations and trial evaluation","author":"Standl","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jfma.2012.09.009_bib13","first-page":"23","article-title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus","volume":"5","author":"Kulasa","year":"2010","journal-title":"Core Evid"},{"key":"10.1016\/j.jfma.2012.09.009_bib14","first-page":"665","article-title":"Optimizing combination treatment in the management of type 2 diabetes","volume":"3","author":"Derosa","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jfma.2012.09.009_bib15","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes. Diabetes Care 2012; http:\/\/dx.doi.org\/10.2337\/dc12-s011.","DOI":"10.2337\/dc12-s011"},{"key":"10.1016\/j.jfma.2012.09.009_bib16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/diacare.26.6.1852","article-title":"Rapid increase in the use of oral antidiabetic drugs in the United States, 1990\u20132001","volume":"26","author":"Wysowski","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2012.09.009_bib17","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/diacare.26.6.1847","article-title":"Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes","volume":"26","author":"Cohen","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2012.09.009_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2710.2006.00705.x","article-title":"Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997\u20132003","volume":"31","author":"Chiang","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jfma.2012.09.009_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/0145721706295021","article-title":"Trends in the prescribing of oral agents for the management for type 2 diabetes mellitus in the United States, 1990\u20132001. Does type of insurance influence access to innovation?","author":"Skaer","year":"2006","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.jfma.2012.09.009_bib20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/BF02849973","article-title":"Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians","volume":"24","author":"Boyc","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.jfma.2012.09.009_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clinthera.2007.02.012","article-title":"Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study","volume":"29","author":"Yurgin","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jfma.2012.09.009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2008.03.009","article-title":"Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data","author":"Mazzaglia","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfma.2012.09.009_bib23","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":"National trends in treatment of type 2 diabetes mellitus, 1994-2007","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2012.09.009_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.1802","article-title":"Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis","volume":"18","author":"Filion","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jfma.2012.09.009_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.24095\/hpcdp.30.3.05","article-title":"Trends in diabetes treatment in Canadians, 1994\u20132004","volume":"30","author":"Neutel","year":"2010","journal-title":"Chronic Dis Can"},{"key":"10.1016\/j.jfma.2012.09.009_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diabres.2011.05.004","article-title":"Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy region: a large population-based study","volume":"93","author":"Baviera","year":"2011","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.jfma.2012.09.009_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.07.033","article-title":"Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications","author":"Desai","year":"2012","journal-title":"Am J Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664612004640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664612004640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T14:56:42Z","timestamp":1643554602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664612004640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0929664612004640"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2012.09.009","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}